These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2574428)

  • 1. The N-methyl-D-aspartate (NMDA) receptor antagonist, dextrorphan, prevents the neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats.
    Finnegan KT; Skratt JJ; Irwin I; Langston JW
    Neurosci Lett; 1989 Nov; 105(3):300-6. PubMed ID: 2574428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of competitive and non-competitive NMDA receptor antagonists in spinal cord injury.
    Faden AI; Ellison JA; Noble LJ
    Eur J Pharmacol; 1990 Jan; 175(2):165-74. PubMed ID: 2155794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats.
    Schmidt CJ; Abbate GM; Black CK; Taylor VL
    J Pharmacol Exp Ther; 1990 Nov; 255(2):478-83. PubMed ID: 1978728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds.
    Colado MI; Green AR
    Br J Pharmacol; 1994 Jan; 111(1):131-6. PubMed ID: 7516800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue.
    Schmidt CJ; Wu L; Lovenberg W
    Eur J Pharmacol; 1986 May; 124(1-2):175-8. PubMed ID: 2424776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons.
    Battaglia G; Yeh SY; De Souza EB
    Pharmacol Biochem Behav; 1988 Feb; 29(2):269-74. PubMed ID: 2452449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.
    Colado MI; Murray TK; Green AR
    Br J Pharmacol; 1993 Mar; 108(3):583-9. PubMed ID: 7682129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chloral hydrate anesthesia antagonizes the neurotoxicity of 3,4-methylenedioxymethamphetamine.
    Schmidt CJ; Black CK; Abbate GM; Taylor VL
    Eur J Pharmacol; 1990 Nov; 191(2):213-6. PubMed ID: 1982264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the 3,4-methylenedioxymethamphetamine-induced changes in neurotensin and dynorphin A systems.
    Johnson M; Bush LG; Gibb JW; Hanson GR
    Eur J Pharmacol; 1991 Feb; 193(3):367-70. PubMed ID: 1675997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog.
    Johnson M; Hanson GR; Gibb JW
    Eur J Pharmacol; 1989 Jun; 165(2-3):315-8. PubMed ID: 2570704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
    Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
    J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors.
    Schmidt CJ; Taylor VL
    Eur J Pharmacol; 1990 May; 181(1-2):133-6. PubMed ID: 1974853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine.
    Schmidt CJ; Black CK; Taylor VL
    Eur J Pharmacol; 1990 May; 181(1-2):59-70. PubMed ID: 1974858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of L-type calcium channel antagonists on the serotonin-depleting actions of MDMA in rats.
    Finnegan KT; Calder L; Clikeman J; Wei S; Karler R
    Brain Res; 1993 Feb; 603(1):134-8. PubMed ID: 8095837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents.
    Hekmatpanah CR; Peroutka SJ
    Eur J Pharmacol; 1990 Feb; 177(1-2):95-8. PubMed ID: 1971219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of dopamine release by methylenedioxymethamphetamine is mediated by serotonin.
    Gazzara RA; Takeda H; Cho AK; Howard SG
    Eur J Pharmacol; 1989 Sep; 168(2):209-17. PubMed ID: 2575036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine.
    Stone DM; Johnson M; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1988 Oct; 247(1):79-87. PubMed ID: 2902215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that both intragastric and subcutaneous administration of methylenedioxymethylamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys.
    Kleven MS; Woolverton WL; Seiden LS
    Brain Res; 1989 May; 488(1-2):121-5. PubMed ID: 2472850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 3,4-methylenedioxymethamphetamine on [3H]paroxetine binding in the frontal cortex and blood platelets of rats.
    Nash JF; Arora RC; Schreiber MA; Meltzer HY
    Biochem Pharmacol; 1991 Jan; 41(1):79-84. PubMed ID: 1702633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats.
    Stone DM; Hanson GR; Gibb JW
    Neuropharmacology; 1987 Nov; 26(11):1657-61. PubMed ID: 2448703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.